Plain-English translation of NCT07263308 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a natural protein found in blood, can improve recovery when combined with emergency clot-removal surgery (endovascular therapy) for acute ischemic stroke. Patients who qualify will be randomly assigned to receive either clot-removal surgery alone or clot-removal surgery combined with . The study will follow participants for 90 days after treatment to measure their recovery and quality of life.
When a blood clot suddenly blocks an artery in the brain, emergency surgery to remove the clot can save brain tissue and reduce disability. Researchers believe this treatment might work even better when combined with , which may help protect brain cells and improve blood flow during and after the procedure.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to one of two groups: one receiving emergency clot-removal surgery only, and the other receiving the same surgery plus infusion. You will undergo brain imaging (CT or MRI scans) and blood tests at the start, receive your assigned treatment, and stay in the hospital for standard stroke care. A study team member will call you 90 days after treatment to ask about your recovery, independence, and quality of life.
AI-generated summary from trial data · Sep 17, 2026 · Not medical advice
China